New drug combo tested for Tough-to-Treat stomach cancers
Disease control
Completed
This study tested whether a new drug called GEN-001, when combined with an existing immunotherapy (avelumab), could help control advanced stomach or gastroesophageal junction cancer. It was for patients whose cancer had progressed after at least two prior standard treatments and …
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC